Nanologica (NICA.ST) Stock Analysis & AI Equity Report
Nanologica (NICA.ST) overview
Nanologica (NICA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Nanologica reported revenue of SEK 21.1m and operating profit of SEK -47.0m; the year-end share price was 0.78 SEK and market capitalisation was SEK 68.9m. Nanologica is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nanologica's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Nanologica
Nanologica AB (publ) develops, manufactures and sells purification media and other consumables for pharmaceutical manufacturers. Its products are designed for preparative chromatography and purification of peptide drugs, including insulin and GLP-1 analogues. The company also works with advanced solutions for developing and manufacturing pharmaceutical substances, with value driven by efficient purification and long product life.
Generate the Nanologica report
Nanologica is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nanologica and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.